ASIA BEAT: Affordability key as China JVs rebound
This article was originally published in Scrip
Executive Summary
Resurgent activity suggests the joint venture approach to business in China is back in vogue despite a lull in major agreements since the last Big Pharma JVs in 2011, and other entry options that might avoid the potential pitfalls.